Calling the piper's tune

Primary Care and Community Psychiatry

Volumn 11, Issue 3, 2006, Pages 147-149

  Menkes, David B ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bias; Commercial influence; Drug trials; Evidence based medicine

Indexed keywords

EID: 39849095434     PISSN: 17468841     EISSN: None     Source Type: Journal    
DOI: 10.1185/135525706X162890     Document Type: Review

References (26)

1. Neale AV, Schwartz KL, Bowman MA. Conflict of interest: can we minimize its influence in the biomedical literature? J Am Board Family Practice 2005;18:411-13 (Pubitemid 41663986)
2. Smith R. Conflicts of interest: how money clouds objectivity. J R Soc Med 2006;99:292-7 (Pubitemid 44013741)
3. Weinstein JN. Conflict of interest: art or science? The hippocratic solution. Spine 2002;27:3-5 (Pubitemid 34219516)
4. Clark JM. The hippocratic oath and the ethics of medicine. JAMA 2004;292:1083-4
5. Smith R. Making progress with competing interests - still some way to go (Editorial). BMJ 2002;325:1375-6 (Pubitemid 35477836)
6. Fulford KW. Values in psychiatric diagnosis: developments in policy, training and research. Psychopathology 2005;38:171-6 (Pubitemid 41254161)
7. Greenwald AG, Pratkanis AR, Leippe MR, Baumgardner MH. Under what conditions does theory obstruct research progress? Psychol Rev 1986;93:216-29
8. Barnes DE, Bero LA. Why Review articles on the health effects of passive smoking reach different conclusions. JAMA 1998;279:1566-70 (Pubitemid 28233013)
9. Baker C, Johnsrud MT, Crismon M, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003;183:498-506 (Pubitemid 37533195)
10. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-76
11. Meiander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171-3 (Pubitemid 36649049)
12. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Mental Dis 2002;190:583-92
13. Moncrieff J, Hopker S, Thomas P. Psychiatry and the pharmaceutical industry: Who pays the piper? Psychiatric Bull 2005;29:84-5 (Pubitemid 40361346)
14. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. J Legal Stud 2005;34:1-25 (Pubitemid 40549835)
15. Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: Issues for clinical investigators. Acad Med 2003;78:769-74 (Pubitemid 36993074)
16. Abraham J. The pharmaceutical industry as a political player. Lancet 2002;360:1498-502 (Pubitemid 35356330)
17. Abraham J. Regulating the drugs industry transparently. BMJ 2005;331:528-9 (Pubitemid 41297309)
18. Mehta V. Batten down the hatches in 2005. Scrip Review of 2004. SCRIP - World Pharmaceut News 2005;3025:57
19. Menkes DB. Psychological defence mechanisms and the nuclear arms race: an interactive model. Med War 1989;5: 80-95
20. Armstrong RW, Williams RJ, Barrett J. The impact of banality, risky shift and escalating commitment on ethical decision making. J Business Ethics 2004;53(4):365-70 (Pubitemid 39337010)
21. Macklin R. Double standards in medical research in developing countries. Cambridge, UK: Cambridge University Press, 2004
22. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87 (Pubitemid 44498387)
23. Luchins DJ. In the aftermath of CAT1E: how should administrators value atypical antipsychotic medications? Adm Policy Ment Health 2006;33:541-3
24. Anonymous. Branding the Cure: A consumer perspective on corporate social responsibility, drug promotion and the pharmaceutical industry in Europe. London: Consumers International, 2006:1-51
25. Smith R, Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clinical Trials 2006;1:1-3
26. Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, Hoffman JR, Ramos J, Jureidini JN. Educating health professionals about drug and device promotion: advocates' recommendations. PLoS Medicine 2006 Nov;3(11):e451